InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
4,604.37
(
0.41%
)
US TECH 100
15,700.80
(
0.54%
)
Dow Jones
36,247.87
(
0.36%
)
Brent Oil
75.97
(
0.00%
)
Bitcoin
44,339.17
(
0.35%
)
Post# of 250008
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (5) Keep Next 10 Report Keyboard Shortcuts
Replies (5) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 788
Posts 118642
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: miljenko post# 232723

Tuesday, 01/26/2021 1:13:41 PM

Tuesday, January 26, 2021 1:13:41 PM

Post# of 250008
VIR—(+40% undeservedly, IMO)—on_interim_phase-1_data_for VIR-3434_in_HBV:

https://www.globenewswire.com/news-release/2021/01/26/2164220/0/en/Initial-Data-from-Ongoing-Phase-1-Trial-of-VIR-3434-for-Chronic-Hepatitis-B-Virus-Infection-Demonstrates-Significant-and-Rapid-Reduction-in-Hepatitis-B-Surface-Antigen.html

The mean reduction in HBsAg (n=6) was 1.3 logs after 8 days. That’s not bad, but neither is it a knock-your-socks-off result. Monotherapy is unlikely to generate a functional cure in HBV, no matter how potent the agent may be against HBsAg.

VIR-3434 is a monoclonal antibody and is VIR’s second HBV agent in the clinic; the first is VIR-2218, an RNAi agent (#msg-155042587).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (5) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (5) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up